Compounds > mk 0663
Page last updated: 2024-09-03

mk 0663 and Hemorrhage, Peptic Ulcer

mk 0663 has been researched along with Hemorrhage, Peptic Ulcer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Soares, J1
Hunt, RH; Yuan, Y1

Reviews

1 review(s) available for mk 0663 and Hemorrhage, Peptic Ulcer

ArticleYear
Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Current pharmaceutical design, 2007, Volume: 13, Issue:22

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Interactions; Endoscopy, Gastrointestinal; Etoricoxib; Humans; Occult Blood; Patient Selection; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pyridines; Risk Assessment; Risk Factors; Sulfones

2007

Other Studies

1 other study(ies) available for mk 0663 and Hemorrhage, Peptic Ulcer

ArticleYear
Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
    Clinical drug investigation, 2009, Volume: 29 Suppl 2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase 2 Inhibitors; Drug Interactions; Duodenal Ulcer; Etoricoxib; Female; Humans; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Pyridines; Sulfones

2009